Ponatinib Hydrochloride



  1. Marketed by Takeda Pharmaceutical Company Limited
  2. Orally bioavailable Bcr-Abl tyrosine kinase inhibitor
  3. Treatment of adult patients with treatment-resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML), accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome–positive (Ph+) CML for which no other kinase inhibitors are indicated, and T315I-positive CML or T315I-positive Ph+ ALL


  1. First U.S. approval: December 14, 2012
  2. First E.U. approval: July 1, 2013

Constraint date forecast:

  1. Patent expiry: 2026 (United States)
  2. Patent expiry: 2027 (Japan)
  3. SPC expiry: 2028 (European Union)

The future of the generics landscape

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team